Takeshi Harada
Overview
Explore the profile of Takeshi Harada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Inoue Y, Oda A, Maeda Y, Sumitani R, Oura M, Sogabe K, et al.
Int J Hematol
. 2024 Apr;
119(6):626-630.
PMID: 38581458
As multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel...
12.
Takahashi M, Kondo S, Kagawa K, Nakamura M, Maeda Y, Sumitani R, et al.
BMJ Support Palliat Care
. 2024 Apr;
14(2):195-199.
PMID: 38569748
Objective: This study investigated whether baseline or alteration in muscle mass affects complications during chemotherapy or overall survival (OS) in haematological malignancies. Methods: Skeletal Muscle Index (SMI) was evaluated by...
13.
Maruhashi T, Miki H, Sogabe K, Oda A, Sumitani R, Oura M, et al.
Int J Hematol
. 2024 Jan;
119(3):291-302.
PMID: 38252236
Hyperthermia is a unique treatment option for cancers. Multiple myeloma (MM) remains incurable and innovative therapeutic options are needed. We investigated the efficacy of hyperthermia and carfilzomib in combination against...
14.
Sogabe K, Nakamura S, Higa Y, Miki H, Oda A, Maruhashi T, et al.
Int J Hematol
. 2024 Jan;
119(3):303-315.
PMID: 38245883
Resistance to proteasome inhibitors (PIs) has emerged as an important clinical issue. We investigated the mechanisms underlying multiple myeloma (MM) cell resistance to PIs. To mimic their pharmacokinetic/pharmacodynamic (PK/PD) profiles,...
15.
Yamagami H, Hara T, Yasui S, Hosoki M, Hori T, Kaneko Y, et al.
Biomedicines
. 2023 Nov;
11(11).
PMID: 38002020
It has previously been unclear whether the accumulation of advanced glycation end products, which can be measured using skin autofluorescence (SAF), has a significant role in diabetic kidney disease (DKD),...
16.
Yasui S, Kaneko Y, Yamagami H, Hosoki M, Hori T, Tani A, et al.
Metabolites
. 2023 Nov;
13(11).
PMID: 37999225
Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. Although skeletal muscle disorders are often found in diabetic people, the clinical significance of DHEAS in skeletal...
17.
Oura M, Harada T, Oda A, Teramachi J, Nakayama A, Sumitani R, et al.
EJHaem
. 2023 Aug;
4(3):667-678.
PMID: 37601887
Adult T-cell leukaemia/lymphoma (ATL) remains incurable. The NF-κB and interferon regulatory factor 4 (IRF4) signalling pathways are among the critical survival pathways for the progression of ATL. TGF-β-activated kinase 1...
18.
Kishimoto H, Iwasaki M, Wada K, Horitani K, Tsukamoto O, Kamikubo K, et al.
iScience
. 2023 Jul;
26(7):107146.
PMID: 37456848
Non-canonical Wnt signaling activated by Wnt5a/Wnt11 is required for the second heart field development in mice. However, the pathophysiological role of non-canonical Wnt signaling in the adult heart has not...
19.
Omichi Y, Toki S, Nishisho T, Harada T, Sato N, Sairyo K
Int J Surg Case Rep
. 2023 Jul;
108:108456.
PMID: 37421768
Introduction And Importance: Denosumab is a new standard treatment for bone disease caused by multiple myeloma. There are a few reports of atypical femoral fracture in patients with multiple myeloma,...
20.
Nashi M, Kishimoto H, Kobayashi M, Tachibana A, Suematsu M, Fujiwara S, et al.
J Dent Sci
. 2023 Jul;
18(3):1156-1163.
PMID: 37404599
Background/purpose: The incidence of medication-related osteonecrosis of the jaw is increasing worldwide, mostly due to the use of antiresorptive agents (ARAs) such as bisphosphonate (BP) and denosumab (Dmab). However, the...